Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Kohei FujitaNaohiro UchidaOsamu KanaiMisato OkamuraKoichi NakataniTadashi MioPublished in: Cancer chemotherapy and pharmacology (2018)
This study suggested that retreatment with anti-PD-1 antibody is a reasonable option for selected NSCLC patients.